Amphastar Pharmaceuticals, Inc. Cash and Restricted Cash
Amphastar Pharmaceuticals, Inc. (AMPH) had Cash and Restricted Cash of $223.85 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $223.85M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $171.17M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $170.41M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $216.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $223.85M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $171.17M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $170.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $216.50M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $187.92M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $183.02M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $151.84M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $192.35M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $189.85M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $201.38M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $144.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $271.04M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $151.28M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $176.85M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $156.33M 10-K · filed 2026-02-26 |
| 2022-09-30 | $157.48M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $166.39M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $172.86M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $126.59M 10-K · filed 2025-03-03 |
| 2021-09-30 | $106.84M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $124.59M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $101.84M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $94.51M 10-K · filed 2024-02-29 |
| 2020-09-30 | $89.78M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $89.25M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $56.71M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $75.55M 10-K · filed 2023-03-01 |
| 2019-09-30 | $87.48M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $122.24M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $80.96M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $88.20M 10-K · filed 2022-03-11 |
| 2018-09-30 | $70.60M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $49.94M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $56.41M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $67.46M 10-K · filed 2021-03-15 |
| 2017-09-30 | $68.78M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $84.41M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $76.89M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $72.35M 10-K · filed 2020-03-16 |
| 2015-12-31 | $66.07M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |